



NEWS RELEASE

Akaal Pharma Receives Approval to Initiate Phase-2 Clinical Trial of Novel Drug Candidate AKP-11 for the Treatment of Psoriasis

MELBOURNE, Australia and SAN DIEGO, CA, USA, June 16, 2015. Akaal Pharma Pty Ltd, (Akaal Pharma), a clinical stage biopharmaceutical company today announced the Human Research Ethics Committee approval to initiate a randomized, double-blind, placebo-controlled Phase-2 clinical trial of its topical drug candidate AKP-11. The patients with mild-to-moderate plaque psoriasis will be treated for six weeks in this study.

“We are pleased with the results of our recently completed Phase-1 clinical trial in which our drug candidate AKP-11 has shown an excellent safety, tolerability and efficacy for treating psoriasis. We look forward to extend the observations in our Phase-2 clinical trial for demonstrating clinical efficacy, safety and tolerability in patients with mild-to-moderate psoriasis. This milestone advances us one step closer to our goal of providing new safer and effective treatments to physicians to help patients with psoriasis and other dermatological conditions,” said Dale Dhanoa, Ph.D., CEO of Akaal Pharma.

About AKP-11

AKP-11 is a novel, small molecule with multimodal mechanism of action that includes S1P₁ modulation and additional anti-inflammatory mechanism of actions. AKP-11 reduces the overexpression of multiple pro-inflammatory cytokines and other factors involved in psoriasis and other skin indications. AKP-11 has shown excellent pharmacokinetic and pharmacodynamics profile and proven safe and efficacious in preclinical and clinical studies. AKP-11 is undergoing development for topical treatment of psoriasis, atopic dermatitis and other skin diseases and dermatological conditions.

About Psoriasis

Psoriasis is one of the most widespread autoimmune/inflammatory skin disorders affecting more than 2% of the global population, with no known cure. Psoriasis is a chronic disease that requires long-term treatment. About 80% of patients have mild-to-moderate psoriasis. The disease is characterized by the presence of red, scaly patches known as psoriatic plaques, which are inflamed and produce excessive skin-cells. Psoriasis and other inflammatory skin disorders are characterized by marked infiltration of leukocytes into the dermis and epidermis, oedema, vascular leak, severe hyperplasia and inflammatory cytokine up-regulation. The current treatments have limited mode of action and suffer from known local and systemic side effects such as skin atrophy and others.

About Akaal

Akaal Pharma Pty Ltd (Akaal Pharma) is a clinical-stage drug discovery and development company focused on the development of novel small molecule drugs for the treatment of inflammatory and immune diseases including psoriasis, atopic dermatitis, multiple sclerosis, ulcerative colitis. Akaal Pharma has created a robust pipeline of novel, multi-action, potent, and highly selective S1P₁ receptor modulators that have shown an excellent oral and topical drug profile. Akaal Pharma applies its medicinal chemistry and drug discovery platform to discover and develop novel, safer and highly effective topical and oral drugs for

the treatment of inflammation and immune diseases with unmet or undermet need. For more information, visit www.akaalpharma.com

Contact

Dale Dhanoa, Ph.D.,
Chief Executive Officer
Akaal Pharma
Thomas Cherry Building - 301E
La Trobe University
Bundoora, VIC-3086
Australia
Direct: +1 858 925-4555 (San Diego, CA, USA)
Tel. +61 3 9479 2584 (Australia)
info@akaalpharma.com